Headache

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.

Does the Location of a Headache Matter?

The location of a headache may be an important factor in identifying the cause of certain types of headaches, but not in all.

Frequent Headaches after a Traumatic Brain Injury

Biofeedback Therapy for Headaches

Cluster Headaches: Treatment and Prevention

Headache Related to Eye Problems

Headache Behind the Eyes: Understanding the Causes

Headaches in Children and Teenagers

What is Medication Overuse Headache?

What is Muscle Contraction Headache?

Headache Evaluation in Children and Teenagers

Can Contact Lenses Cause Headaches?

Migraine with Aura vs. Migraine without Aura

Latest Headache News and Research

Foreign-born Black adults show lower stroke risk than Americans

For Black individuals in the United States, being born in another country was associated with a lower risk of stroke, according to a study published July 15, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

15 Jul 2026

Irritable patients changed physicians’ emotions but not decisions

Irritable patient behavior influences physician emotions but does not alter clinical assessments, emphasizing the need for emotional resilience training.

15 Jul 2026

High physician knowledge scores linked to lower healthcare costs

Patients whose physicians scored higher in the first year of the American Board of Internal Medicine's (ABIM) Internal Medicine Longitudinal Knowledge Assessment (LKA) were significantly less likely to receive low-value healthcare services, which cumulatively cost the U.S. healthcare system an estimated $100 billion each year.

13 Jul 2026

Rising tick-borne disease in Canada can trigger heart inflammation

Move over, Lyme disease - there's another tick-borne disease to worry about in Canada. Anaplasmosis, the second most common tick-borne disease in the country, can cause a range of health issues, including myocarditis (inflammation of the heart muscle).

13 Jul 2026

Robot-guided surgery successfully drains multiple deep brain abscesses

Brain abscesses located deep within the brain can rapidly become life-threatening and are often difficult to treat through conventional surgery. Brain abscesses located deep within the brain can rapidly become life-threatening and are often difficult to treat through conventional surgery.

13 Jul 2026

Ear acupuncture may reduce migraine pain, study suggests

Acupuncture to the ear may help to lessen pain from migraines and their impact on daily life, according to new research presented today (Friday) at the Federation of European Neuroscience Societies (FENS) Forum 2026.

9 Jul 2026

Early-onset dementia lowers work productivity years before formal diagnosis

People diagnosed with early-onset dementia had reduced work productivity up to 15 years before diagnosis, according to a study published July 8, 2026, in Neurology, the medical journal of the American Academy of Neurology.

9 Jul 2026

Researchers identify a distinct subtype of eosinophilic esophagitis in children

Researchers from Ann & Robert H. Lurie Children's Hospital of Chicago identified a distinct subtype of eosinophilic esophagitis (EoE) – a chronic allergic inflammatory disorder in which the esophagus narrows, interfering with food going down properly.

6 Jul 2026

Genetic testing could sharply increase demand for ALS specialist care

The availability of genetic testing for amyotrophic lateral sclerosis (ALS) for people with a family member diagnosed with the disease is expected to greatly increase the number of clinic visits to specialized ALS centers over the next decade, according to a study published June 24, 2026, in Neurology Genetics, an official journal of the American Academy of Neurology.

24 Jun 2026

Trial identifies 4 grams a day as the tested safe level for L-tyrosine in healthy men

A randomized, crossover trial in healthy adult men found that 4 weeks of L-tyrosine supplementation at doses up to 4 g/day did not cause clinically meaningful changes in safety markers, diet, blood pressure, or body measures. The highest tested dose, 4 g/day, was identified as the no-observed-adverse-effect level under the study’s four-week conditions, although broader and longer-term studies are still needed.

23 Jun 2026

How clinicians can identify and manage Ebola, hantavirus

Two deadly infectious diseases, Ebola https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260834 and hantavirus https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260789, have made headlines in recent weeks as they pose serious threats to public health.

22 Jun 2026

Neurological disorders may raise traumatic brain injury risk in older adults

For traumatic brain injury (TBI) and certain brain diseases, it looks like the risk may go in both directions, according to a study published on June 17, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

17 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

Migraine affects driving more often than clinicians may realize

A multicenter study of 1,333 active drivers with migraine found that 70.6% had experienced headache while driving, with headaches occurring during about 13% of driving sessions. The findings suggest that migraine-related symptoms may impair attention, increase sensitivity to road conditions, and contribute indirectly to driving cessation and accident risk.

15 Jun 2026

Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.

13 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Many stroke patients miss intensive rehabilitation after hospitalization

Fewer than one in four people with stroke and fewer than one in seven people with traumatic brain injury receive inpatient rehabilitation care after being hospitalized, according to a study published on June 10, 2026, in Neurology Open Access, an official journal of the American Academy of Neurology.

10 Jun 2026

Elevated blood pressure linked to lower dementia risk in people with physical frailty

For people with physical frailty, having high blood pressure may be associated with a lower risk of dementia, according to a study published on June 10, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

10 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

New project launches to advance chikungunya vaccine in Africa

Funded by the Global Health EDCTP3 Joint Undertaking, a new €15.3 million project coordinated by Institut Pasteur brings together seven partners across four continents to advance clinical trials and prepare for the manufacturing of a chikungunya vaccine in Africa.

8 Jun 2026